Abstract

Substantial evidences from epidemiological and animal-based studies indicate that early exposure to endocrine disrupting chemicals (EDCs) during the developmental stage results in a variety of disorders including cancer. Previous studies have demonstrated that early estrogen exposure results in life-long reprogramming of the prostate gland that leads to an increased incidence of prostatic lesions with aging. We have recently documented that bisphenol A (BPA), one of the most studied EDCs with estrogenic activity has similar effects in increasing prostate carcinogenic potential, supporting the connection between EDCs exposure and prostate cancer risk. It is well accepted that stem cells play a crucial role in development and cancer. Accumulating evidence suggest that stem cells are regulated by extrinsic factors and may be the potential target of hormonal carcinogenesis. Estrogenic EDCs which interfere with normal hormonal signaling may perturb prostate stem cell fate by directly reprogramming stem cells or breaking down the stem cell niche. Transformation of stem cells into cancer stem cells may underlie cancer initiation accounting for cancer recurrence, which becomes a critical therapeutic target of cancer management. We therefore propose that estrogenic EDCs may influence the development and progression of prostate cancer through reprogramming and transforming the prostate stem and early stage progenitor cells. In this review, we summarize our current studies and have updated recent advances highlighting estrogenic EDCs on prostate carcinogenesis by possible targeting prostate stem/progenitor cells. Using novel stem cell assays we have demonstrated that human prostate stem/progenitor cells express estrogen receptors (ER) and are directly modulated by estrogenic EDCs. Moreover, employing anin vivohumanized chimeric prostate model, we further demonstrated that estrogenic EDCs initiate and promote prostatic carcinogenesis in an androgen-supported environment. These findings support our hypothesis that prostate stem/progenitor cells may be the direct targets of estrogenic EDCs as a consequence of developmental exposure which carry permanent reprogrammed epigenetic and oncogenic events and subsequently deposit into cancer initiation and progression in adulthood.

Highlights

  • Prostate cancer is the most diagnosed male non-cutaneous malignancy in the Western world [1 - 3]

  • By using our in vivo humanized chimeric prostate renal graft model, We have recently demonstrated that developmental exposure to low dose bisphenol A (BPA) increases hormonedependent cancer risk in the prostate epithelium derived from human prostate stem/progenitor cells [28]

  • We have previously demonstrated that human prostate stem and progenitor cells positively express estrogen receptors (ERα, ERβ and GPR30) [10]. qPCR analysis revealed that ERβ expression increased in days 30 prostasphere as compared to days 7 prostasphere

Read more

Summary

Introduction

Prostate cancer is the most diagnosed male non-cutaneous malignancy in the Western world [1 - 3]. By using our in vivo humanized chimeric prostate renal graft model, We have recently demonstrated that developmental exposure to low dose BPA increases hormonedependent cancer risk in the prostate epithelium derived from human prostate stem/progenitor cells [28].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call